Article
Fort Worth, TX-A third generic version of brimonidine tartrate ophthalmic solution 0.2% now gives ophthalmologists yet another alternative for lowering IOP in patients with open-angle glaucoma or ocular hypertension.
ARVO announces Swathi Kaliki, MD, as recipient of 2025 Ludwig von Sallmann Clinician-Scientist Award
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Survey reveals gaps in patient awareness of preservative-free glaucoma treatments
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Harrow to enact a 5-year strategic supply and development agreement for triamcinolone acetonide injectable suspension
Tenpoint Therapeutics Ltd. appoints Carol Kearney as Chief Commercial Officer